14.2 Clinical Trials in Breast Oncology

CBCN Certified Breast Care Nurse Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CBCN Exam

CBCN Exam Facts, 2026 Blueprint & Study Plan

2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)

1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes

3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)

2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations

4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)

3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation

5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)

4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance

6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)

5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques

7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)

6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification

8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)

7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET

9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)

8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery

10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)

9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens

11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)

10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs

12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)

11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations

13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)

12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy

14 Chapter 13: Oncologic Emergencies (Nursing Practice)

13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism

15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)

14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use

16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)

15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health

14.2 Clinical Trials in Breast Oncology

Key Takeaways Explain This Topic AI

Phase I trials find safe doses, phase II trials look for activity, phase III trials compare a new treatment with the standard of care, and phase IV studies monitor safety after approval.

Informed consent for research is an ongoing process that includes purpose, procedures, risks, benefits, alternatives, confidentiality, and the right to withdraw at any time without penalty.

Institutional review boards oversee research ethics, and adverse events are graded with the NCI Common Terminology Criteria for Adverse Events (CTCAE).

The Affordable Care Act requires most health plans to cover routine patient care costs for people enrolled in approved clinical trials.

Common trial endpoints include overall survival, invasive disease-free survival, progression-free survival, pathologic complete response, and patient-reported outcomes.

Last updated: September 2026

Why Trials Matter to Breast Care Nurses

Nearly every standard therapy in this guide, from sentinel node biopsy to CDK4/6 inhibitors, was proven in clinical trials. Nurses identify eligible patients, explain trials, support informed consent, deliver protocol treatment, assess and report adverse events, and advocate for participants.

Trial Phases

Advances in breast cancer survival depend upon rigorous clinical trials. Breast care nurses educate patients regarding trial phases and advocate for equitable participation:

Phase I Trials : Evaluate the safety profile, determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D), assess pharmacokinetics/pharmacodynamics, and identify acute toxicities of a novel agent in small patient cohorts (typically 15 to 30 patients).

Phase II Trials : Evaluate the preliminary therapeutic efficacy of a drug against specific breast cancer subtypes and further characterize safety and side-effect profiles (typically 50 to 100 patients).

Phase III Trials : Compare the new investigational therapy against the current established standard-of-care therapy in large, randomized, multicenter patient cohorts (hundreds to thousands of patients) to determine definitive improvements in disease-free survival, progression-free survival, and overall survival.

Phase IV Trials : Post-marketing surveillance conducted after FDA approval to evaluate long-term safety, rare toxicities, and therapeutic effectiveness in broad, real-world patient populations.

Overcoming Barriers to Participation

Racial and ethnic minorities are historically underrepresented in cancer clinical trials, and Black patients in particular make up a much smaller share of breast cancer trial participants than of people living with the disease. Breast care nurses address trial enrollment barriers by:

Dismantling Placebo Misconceptions : Clarifying for patients that therapeutic cancer trials never utilize a placebo alone when an effective standard-of-care therapy exists; investigational agents are added to standard therapy or compared directly against standard care.

Addressing Logistical Hurdles : Working with trial coordinators to arrange transportation, lodging, and flexible visit windows.

Fostering Trust : Providing culturally sensitive, unhurried education that respects historical community concerns regarding medical exploitation.

Trial Design Basics

Randomization assigns participants to arms by chance to balance known and unknown factors.

Blinding keeps participants and/or investigators unaware of assignments to reduce bias; double-blind trials blind both.

Control arms use the current standard of care. When no effective standard exists, a placebo may be used, but in cancer treatment trials a placebo is usually added to standard therapy (for example, placebo plus endocrine therapy) rather than given alone.

Phase 0 studies give tiny doses to study drug behavior without therapeutic intent.

Common Endpoints

• Endpoint Meaning
• Overall survival (OS) Time to death from any cause; the gold standard

Invasive disease-free survival (iDFS) Time to invasive recurrence, new invasive cancer, or death; common in adjuvant trials

• Progression-free survival (PFS) Time to disease progression or death; common in metastatic trials
• Pathologic complete response (pCR) No residual invasive cancer in breast and nodes after neoadjuvant therapy
• Objective response rate (ORR) Proportion with tumor shrinkage meeting criteria
• Patient-reported outcomes (PROs) Symptoms, function, and quality of life reported by participants
• Informed Consent and Oversight

Federal regulations (the Common Rule and FDA regulations) and Good Clinical Practice require that consent documents and discussions cover the study's purpose and duration, procedures, foreseeable risks and discomforts, possible benefits, alternatives (including standard treatment and no treatment), confidentiality, compensation for injury, whom to contact, and the fact that participation is voluntary and the participant may withdraw at any time without losing benefits or standard care .

Consent is a process, not a signature: information is repeated and updated when new risks emerge (re-consent). Nurses watch for therapeutic misconception , when a participant believes the trial is designed mainly to benefit them personally rather than to answer a scientific question. Institutional review boards (IRBs) approve and monitor studies, and data and safety monitoring boards review accumulating results.

Adverse Event Assessment and Reporting

Adverse events are graded with the NCI Common Terminology Criteria for Adverse Events (CTCAE) , from grade 1 (mild) to grade 5 (death). The investigator attributes each event (unrelated to definitely related). Serious adverse events (death, life-threatening events, hospitalization, disability, congenital anomaly) must be reported to the sponsor and IRB within protocol timelines, often 24 hours for initial notice. Accurate, contemporaneous nursing documentation is essential.

Nursing Roles

Research nurses screen eligibility, coordinate visits, ensure protocol-specified labs and imaging happen on schedule, maintain drug accountability, and document precisely.

Treating nurses administer investigational agents per protocol, recognize unexpected toxicities, and report deviations.

All nurses raise awareness of trials, use resources such as ClinicalTrials.gov and NCI cooperative groups (for example, NRG Oncology, SWOG, Alliance, and ECOG-ACRIN) and the NCI Community Oncology Research Program, and protect participants' rights.

Coverage and Access

The Affordable Care Act requires most private plans to cover routine patient care costs for participants in approved trials, and Medicare covers routine costs under its clinical trial policy. Sponsors usually cover the investigational drug and research-only tests. Travel, lodging, and time off work remain barriers that navigators and trial coordinators help address.

Special Protections in Research

Trials exclude or add safeguards for pregnant people, and most require pregnancy testing and effective contraception during and after investigational therapy. Adults who cannot consent need a legally authorized representative, and research use of health information requires a HIPAA authorization. Newer trials may use decentralized elements, such as home nursing visits, local labs, and telehealth consent, which can reduce travel burden but still require the same protections.